Shajari Rasoul, Adeli Seyed Hasan, Bagherzadeh Mohammad, Asghari Akram, Tabaraii Reihane, Alikhani Aliakbar, Jabbari Amir, Razavinia Fateme, Shakeri Mansoureh, Jafari Saeede, Ahmadpour Sajjad, Vafaeimanesh Jamshid
Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
Student Research Committee, Qom University of Medical Sciences, Qom, Iran.
J Educ Health Promot. 2023 Apr 28;12:129. doi: 10.4103/jehp.jehp_332_21. eCollection 2023.
So far, several protocols have been used for the treatment of coronavirus disease-2019 (COVID-19). In this study, we aimed to study the effect of interferon on the treatment of hypoxemia caused by COVID-19.
This was a quasi-experiment with a nonequivalent group design. All participants were admitted to Shahid Beheshti Hospital, Qom province. In total, 60 patients were enrolled in the study, and inclusion criteria were age over 18 years, positive PCR test result, pulmonary involvement in computed tomography (CT) scan, and SpO level below 93%. Individuals were divided into two control (hydroxychloroquine + lopinavir/ritonavir [Kaletra]) and intervention (hydroxychloroquine + lopinavir/ritonavir [Kaletra] + interferon-β 1a [recigen]) groups. The data were analyzed in Stata/SE 14.2 using Chi-square, -test, and Mann-Whitney test.
The mean ± standard deviation (SD) age of patients was 63 ± 16.12 years and 43.3% were male. In terms of outcome variables, 20% of patients in the intervention group and 53.3% of subjects in the control group died and this difference was significant ( = 0.007). According to the quick sequential organ failure assessment (qSOFA) score, the severe cases were 16.7% in the intervention group and 50% in the control group ( = 0.006). In addition, the median days of hospitalization were 11.5 days-significantly higher than those in the control group (5.5 days) ( < 0.001).
Based on the results of this study, the use of interferon in the treatment of COVID-19 can improve health and reduce the severity of the disease and mortality.
到目前为止，已有多种方案用于治疗2019冠状病毒病（COVID-19）。在本研究中，我们旨在研究干扰素对治疗COVID-19所致低氧血症的效果。
这是一项采用非等效组设计的准实验。所有参与者均入住库姆省的沙希德·贝赫什提医院。共有60名患者纳入本研究，纳入标准为年龄超过18岁、聚合酶链反应（PCR）检测结果呈阳性、计算机断层扫描（CT）显示肺部受累以及血氧饱和度（SpO）水平低于93%。个体被分为两个对照组（羟氯喹 + 洛匹那韦/利托那韦 [克力芝]）和干预组（羟氯喹 + 洛匹那韦/利托那韦 [克力芝] + 干扰素-β １ａ [利比隆]）。数据在Stata/SE 14.2中使用卡方检验、ｔ检验和曼-惠特尼检验进行分析。
患者的平均年龄±标准差（SD）为63±16.12岁，男性占43.3%。就结局变量而言，干预组20%的患者和对照组53.3%的受试者死亡，这一差异具有统计学意义（P = 0.007）。根据快速序贯器官衰竭评估（qSOFA）评分，干预组重症病例为16.7%，对照组为50%（P = 0.006）。此外，住院天数中位数为11.5天，显著高于对照组（5.5天）（P < 0.001）。
基于本研究结果，使用干扰素治疗COVID-19可改善健康状况，降低疾病严重程度和死亡率。
